GleamWall
中文EN

RARE Ultragenyx Pharmaceutical Inc.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1515673 · Fiscal year ends 12/31

Financial factors as of 2025-12-31 (2025Q4), TTM = sum of the last four quarters

Growth

TTM revenue YoY20.2%
TTM net income YoY-0.9%
TTM EPS YoY7.3%
Revenue 3-yr CAGR22.8%
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin-79.5%
Net margin-85.3%
FCF margin-70.1%
EBITDA margin-74.3%

Returns

ROE-656.6%
ROA-37.9%
ROIC (approx.)—
Asset turnover0.44x

Leverage & solvency

Liabilities / assets104.8%
Debt / equity—
Current ratio2.48x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.81x
Accruals ratio-7.2%
Payout ratio—
Capex / revenue0.9%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-09-302026Q22026-06-302026Q12026-03-312025Q4*2025-12-312025Q32025-09-302025Q22025-06-302025Q12025-03-312024Q4*2024-12-31
Income statement
Revenue$173.00M$214.00M$136.00M$207.28M$160.00M$167.00M$139.00M$164.88M
R&D expense$154.00M$167.00M$187.00M$203.28M$216.00M$165.00M$166.00M$187.77M
SG&A expense$97.00M$88.00M$88.00M$87.94M$87.00M$87.00M$87.00M$82.50M
Operating income-$110.00M-$75.00M-$169.00M-$113.28M-$171.00M-$108.00M-$143.00M-$122.28M
Pretax income-$127.00M-$91.00M-$184.00M-$128.00M-$179.00M-$114.00M-$150.00M-$133.40M
Income tax-$9.00M$1.00M$1.00M$870,000$1.00M$1.00M$1.00M-$19,000
Net income-$118.00M-$92.00M-$185.00M-$128.56M-$180.00M-$115.00M-$151.00M-$133.38M
EBITDA-$101.00M-$67.00M-$161.00M-$104.50M-$163.00M-$99.00M-$134.00M-$113.20M
EPS (basic)-1.16-0.90-1.84—-1.81-1.17-1.57—
EPS (diluted)-1.16-0.90-1.84—-1.81-1.17-1.57—
Weighted avg. shares (diluted)102.10M101.90M100.60M—99.80M98.50M96.30M—
Balance sheet
Cash & equivalents$150.00M$125.00M$175.00M$421.00M$203.00M$176.00M$127.00M$174.00M
Short-term investments$116.00M$167.00M$238.00M$259.00M$222.74M$311.28M$367.38M$436.00M
Receivables$166.00M$200.00M$121.00M$158.00M$112.54M$124.46M$98.84M$122.00M
Inventory$59.00M$59.00M$55.00M$52.00M$52.20M$46.50M$46.03M$45.00M
Current assets$544.00M$606.00M$657.00M$951.00M$643.21M$719.79M$699.15M$817.00M
PP&E, net$231.00M$235.00M$239.00M$244.00M$249.96M$255.76M$260.91M$266.00M
Goodwill$44.00M$44.00M$44.00M$44.00M$44.41M$44.41M$44.41M$44.00M
Intangibles$170.00M$172.00M$174.00M$176.00M$172.94M$174.73M$176.52M$178.00M
Total assets$1.19B$1.26B$1.30B$1.53B$1.19B$1.31B$1.31B$1.50B
Current liabilities$389.00M$351.00M$325.00M$384.00M$340.02M$293.24M$291.67M$344.00M
Total liabilities$1.56B$1.55B$1.52B$1.60B$1.17B$1.15B$1.16B$1.24B
Shareholders' equity-$376.00M-$291.00M-$236.00M-$80.00M$10.00M$151.00M$144.00M$255.00M
Shares outstanding101.90M98.60M98.30M96.60M96.44M96.35M93.90M92.50M
Cash flow statement
Operating cash flow-$43.00M-$97.00M-$197.00M-$99.83M-$91.00M-$109.00M-$166.00M-$79.50M
Capital expenditure$2.00M$1.00M$1.00M$938,000$1.00M$3.00M$1.00M$654,000
Free cash flow-$45.00M-$98.00M-$198.00M-$100.77M-$92.00M-$112.00M-$167.00M-$80.16M
Investing cash flow$58.00M$44.00M-$49.00M-$72.25M$117.00M$71.00M$120.00M$102.73M
Financing cash flow$10.00M——$394.19M$0$83.65M$157,000$3.19M
Depreciation & amortization$9.00M$8.00M$8.00M$8.79M$8.00M$9.00M$9.00M$9.08M
Stock-based compensation$34.00M$34.00M$30,000$37.47M$37.00M$39.00M$40,000$40.19M

Free plan shows the latest 8 periods; Pro shows all 55 🔒

· This company does not report gross profit in XBRL.

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.